Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Ionescu M. A. 1, Baroni A. 2, Brambilla L. 3, Cannavò S. P. 4, Cristaudo A. 5, Dalle Vedove C. 6, Frasca M. 5, Girolomoni G. 6, Gnecchi L. 7, Peris K. 8, Trifirò C. 4, Matta A. M. 9, Robert G. 9
1 Dermatology Polyclinic, Saint-Louis Hospital, Paris, France;
2 Unit of Dermatology, University of Naples, Naples, Italy;
3 Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy;
4 Dermatological Clinic, University of Messina, Messina, Italy;
5 San Gallicano Dermatological Clinic, Rome, Italy;
6 Dermatological Clinic, University of Verona, Verona, Italy;
7 S. Gerardo University Hospital, Monza, Italy;
8 Dermatological Clinic, University of L’Aquila, L’Aquila, Italy;
9 Laboratoires Dermatologiques d’Uriage Courbevoie, France
AIM: Seborrheic dermatitis is a chronic inflammatory disease aggravated by Malassezia species. Toll-like receptors (TLR) are part of innate immune system that can be activated by yeasts. Previous studies showed that an association of Ombelliferae extract with a lipid (TLR2-RegulTM) decreases the IL-8 expression in human skin in contact with M. furfur. The aim of this study was to assess the activity of a topical formulated with TLR2-RegulTM in the prevention of seborrheic dermatitis (SD) relapses.
METHODS: Immune-competent SD adult patients were treated for SD (topical imidazoles or steroids). Cleared patients were randomized and received a topical containing TLR2-RegulTM (A) or its vehicle (B). Erythema, scales and pruritus were assessed during two months.
RESULTS: The study included 115 patients, mean age 43.4, sex ratio m/f 1.5. At week 4 the relapse rate was 26% (N.=15) in group A and 43% (N.=25) in group B. At W8 the relapse rate was 21% (N.=12) in group A and 40% (N.=23) (P=0.0309).
CONCLUSION: In this series of 115 adults with seborrheic dermatitis, patients treated with a topical containing TLR-RegulTM showed a significantly less relapse rate compared with the excipient group (P<0.05). TLR modulation could represent a new therapeutic approach in the prevention of seborrheic dermatitis relapses.